美阿沙坦钾杂质B | 1417576-00-1

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 美阿沙坦钾杂质B
• 中文别名: 美阿沙坦钾
• 英文名称: (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-oxo-3-((2′-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl)-methyl)-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate
• 英文别名: (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-oxo-3-((2’-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-[1,1’-biphenyl]-4-yl)methyl)-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate；Desethyl Azilsartan Medoxomil；(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-oxo-3-[[4-[2-(5-oxo-4H-1,2,4-oxadiazol-3-yl)phenyl]phenyl]methyl]-1H-benzimidazole-4-carboxylate
• CAS: 1417576-00-1
• 化学式: C₂₈H₂₀N₄O₈
• 分子量: 540.489
• InChiKey: MZPRTKPTVHPGEW-UHFFFAOYSA-N

物化性质

• 密度：
  1.54±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（轻微）、甲醇（轻微、加热）

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  40
• 可旋转键数：
  8
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  145
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  阿齐沙坦 在 盐酸 、 4-二甲氨基吡啶 、 potassium carbonate 、 对甲苯磺酰氯 作用下， 以 N,N-二甲基乙酰胺 、 水 、 丙酮 为溶剂， 反应 4.0h， 生成 美阿沙坦钾杂质B
  参考文献：
  名称：

  Improved Process for Azilsartan Medoxomil: A New Angiotensin Receptor Blocker

  摘要：

  An improved process for the active pharmaceutical ingredient of a new angiotensin II AT(1) receptor antagonist, azilsartan medoxomil, has been developed. The results include reinvestigation of the described process as well as its novel modifications. This new process includes transformation of the CN group into amidoxime moiety by aqueous hydroxylamine, its cyclization into the corresponding oxadiazole by treatment with dialkyl carbonates, and the following hydrolysis of the ester and transformation into the medoxomil ester. Several thus far undocumented side products were identified, and some of them were synthesized and duly characterized as potential impurities. Formation and control of possible critical impurities are described.

  DOI：

  10.1021/op3002867

文献信息

• Liquid chromatography/tandem mass spectrometry study of forced degradation of azilsartan medoxomil potassium
  作者：Debasish Swain、Prinesh N. Patel、Ilayaraja Palaniappan、Gayatri Sahu、Gananadhamu Samanthula

  DOI：10.1002/rcm.7235

  日期：2015.8.15

  Azilsartan medoxomil potassium (AZM) is a new antihypertensive drug introduced in the year 2011. The presence of degradation products not only affects the quality, but also the safety aspects of the drug. Thus, it is essential to develop an efficient analytical method which could be useful to selectively separate and identify the degradation products of azilsartan medoxomil potassium.

  Azilsartan medoxomil钾（AZM）是一种于2011年推出的新型降压药。降解产物的存在不仅影响药物的质量，还影响其安全性。因此，至关重要的是开发一种有效的分析方法，该方法可用于选择性地分离和鉴定阿齐沙坦美多西莫钾的降解产物。
• PROCESS FOR THE PREPARATION AND PURIFICATION OF AZILSARTAN MEDOXOMIL
  申请人：CADILA HEALTHCARE LIMITED

  公开号：US20140113942A1

  公开（公告）日：2014-04-24

  The present invention relates to process an improved process for the preparation of azilsartan medoxomil. In particular, the field of invention relates to a process for purification of azilsartan medoxomil. More particularly, the invention relates to an improved process for preparation of azilsartan medoxomil and its pharmaceutically acceptable salts.

  本发明涉及一种改进的阿齐嗪酸美托米尔制备工艺。具体而言，本发明领域涉及阿齐嗪酸美托米尔的纯化工艺。更具体地说，本发明涉及一种改进的阿齐嗪酸美托米尔及其药学上可接受的盐的制备工艺。